Rare blood disorder prevalence is driving the Soliris Market 2026

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Soliris Market In 2026 And What Value Is Projected For 2030?

The Soliris market has experienced substantial expansion in recent years. It is forecast to grow from $2030.44 million in 2025 to $2191.9 million in 2026, at a compound annual growth rate (CAGR) of 8.0%. The past growth can be ascribed to unaddressed needs in rare diseases, clinical achievements in PNH and AHUS, regulatory incentives for orphan drugs, improved patient survival outcomes, and limited available therapeutic options.

The soliris market is projected to experience substantial expansion in the coming years, reaching $2941.58 million by 2030, exhibiting a compound annual growth rate (CAGR) of 7.6%. This anticipated growth stems from factors such as the broadening of treatment areas to include more complement mediated diseases, increasing recognition of rare diseases, advancements in genetic diagnostics, enhanced financial support for orphan drugs in healthcare, and the implementation of long-term therapy adherence initiatives. Key developments expected during this period involve the increasing uptake of complement inhibitor treatments, a heightened emphasis on ultra rare diseases, wider application of long-term biologic therapies, an escalation in genetic screening for uncommon conditions, and the expansion of the high value orphan drug sector.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19933&type=smp

What Key Drivers Are Influencing The Growth Of The Soliris Market?

The rising incidence of rare blood disorders is projected to fuel the expansion of the soliris market. These uncommon conditions, which include hemophilia, sickle cell anemia, and thalassemia, impact the blood’s formation, constituents, or coagulation. The surge in these disorders stems from enhanced diagnostic methods, heightened public understanding, and various genetic and environmental influences. Soliris aids individuals with rare blood disorders by blocking the complement protein C5, thereby averting excessive complement activation. This action lessens the chance of severe issues such as hemolysis and organ damage, ultimately enhancing disease control and patient results. As an illustration, data from the National Health Service (NHS) England, a government-funded healthcare provider in the UK, revealed in May 2024 that about 17,000 individuals in England have sickle cell disease, an inherited blood condition, with approximately 250 new diagnoses occurring each year. Consequently, the increasing occurrence of rare blood disorders is stimulating the growth of the soliris market. Increased funding into rare disease research is anticipated to drive the expansion of the Soliris market moving forward. The escalation in rare disease research investment is primarily due to a greater awareness of unaddressed medical requirements, progress in genomics, and the prospect of developing innovative treatments that can better patient well-being. This investment in rare disease research supports Soliris by broadening comprehension of conditions that lack sufficient treatment options, thus boosting the need for potent therapeutic solutions. For example, in July 2023, the Department of Health and Science Care, a UK government body, allocated substantial financial resources, including USD 834.20 million (£790 million) for Biomedical Research Centers, $15.06 million (£12 million) for the UK Rare Disease Research Platform, and $50.20 million (£40 million) for the NIHR BioResource, which facilitates linking genetic information with clinical characteristics across 50 rare diseases to advance diagnosis and treatment development. Hence, the increasing investment in rare disease research is fueling the Soliris market’s growth.

What Are The Key Segments Of The Soliris Market?

The soliris market covered in this report is segmented –

1) By Type: Plasma Exchange, Plasma Infusion

2) By Application: Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (AHUS)

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What Key Trends Are Influencing The Development Of The Soliris Market?

The central trend in the soliris market revolves around developing biologic medicines for neuromyelitis optica spectrum disorder (NMOSD) to improve treatment options for rare blood disorders. This constitutes a notable advancement in the handling of NMOSD, a rare and severe autoimmune condition impacting the central nervous system, by providing an effective therapy to decrease relapses and prevent further neurological deterioration. For example, in October 2023, AstraZeneca PLC, a UK-based pharmaceutical company, received approval for Soliris (eculizumab) from the National Medical Products Administration (NMPA) in China for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are positive for anti-aquaporin-4 (AQP4) antibodies (Ab+). This marks it as the first and only complement inhibitor approved for NMOSD treatment in China.

Who Are The Leading Companies Operating In The Soliris Market?

Major companies operating in the soliris market are Pfizer

Read the full soliris market report here:

https://www.thebusinessresearchcompany.com/report/soliris-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Soliris Market?

North America was the largest region in the Soliris market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the soliris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Soliris Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19933&type=smp

Browse Through More Reports Similar to the Global Soliris Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Membrane Filtration Market Report 2026

https://www.thebusinessresearchcompany.com/report/membrane-filtration-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795